Alopexx is a clinical-stage biotechnology company developing a vaccine and an antibody against PNAG, a surface molecule shared by more than 75 pathogens. Our aim is to reduce the world's reliance on antibiotics.
Immune therapeutics are not associated with the development of resistance and are not excreted into the environment. That makes them a durable complement to the antibiotics hospitals depend on today.
PNAG, or poly N-acetyl glucosamine, helps microbes stick to tissue and implanted devices and shields them from the immune system. Most vaccines target a coat unique to one strain. PNAG appears across an expanding list of pathogens.
Natural PNAG is heavily acetylated, which provokes a weak immune response. Our therapeutics target its de-acetylated backbone instead, inducing antibodies that kill PNAG-bearing microbes. The work began with Dr. Gerald Pier and his team at Harvard Medical School and Brigham and Women's Hospital.
An antibody for immediate protection and a vaccine for lasting protection, plus related formulations for neuroinflammatory disease.
Designed to prevent and mitigate hospital-associated infections in ICU patients. A single infusion has provided antibody coverage for two to three months.
A complement to approved pneumococcal vaccines, which cover at most 23 of the 100 known serotypes.
Related antibody and vaccine formulations for Alzheimer's disease and other neuroinflammatory conditions.
deaths worldwide were associated with bacterial antimicrobial resistance in 2019, making it the third leading cause of death.
The Lancet, 2022 global burden analysis of 204 countries"With the increasing incidence of antimicrobial resistant bacteria there is a pressing need for novel and alternative therapeutics."Daniel R. Vlock, MD, Co-Founder and Chief Executive Officer, at IDWeek 2023
Europe's largest hospital system has agreed to run the 1,600-patient phase 2 study of F598 across eight of its hospitals.
Co-development and commercialization of AV0328 in India and other low and lower-middle income countries.
Alopexx exclusively licenses issued patents covering the vaccine, the F598 antibody and their methods of use.
PNAG has been found in the brains of patients with Alzheimer's disease and traumatic brain injury, where no live pathogen can be grown. We believe microbial fragments carrying PNAG drive chronic inflammation in these conditions.
In mouse models, vaccination against PNAG prevented cognitive decline. Our AB0411 and AV0407 formulations are designed to bring that approach to patients.
Co-developed F598 and AV0328 with Dr. Gerald Pier. Former senior roles at Pharmacia, Boehringer Ingelheim and GPC Biotech.
Former Corporate Treasurer of Genentech and audit committee chair at Opiant Pharmaceuticals.
Twelve years leading licensing and development at Pfizer; founder of Biotech Partnering Solutions.
For clinical, partnering and investor inquiries, our team in Cambridge, Massachusetts is ready to talk.
